Mannose derivatives for treating bacterial infections

A method of treating or preventing a bacteria infection in a subject, comprising administering to a patient in need thereof from 0.01 to about 100 mg/kg body weight/day of a compound of formula (I) or a pharmaceutically acceptable salt thereof:

• Z is
• Ring H is an optionally substituted 5-6 membered aromatic monocyclic ring optionally having 1-4 heteroatoms selected from nitrogen, or sulfur;
• an 8-12 membered aromatic bicyclic ring optionally having 1-6 heteroatoms selected from oxygen, nitrogen, or sulfur;
• or a 10-14 membered aromatic tricyclic ring optionally having 1-6 heteroatoms selected from oxygen, nitrogen, or sulfur;
• L2 is —X2Y2— wherein X2 is a C1aliphatic or —C(O)— and Y2 is C1-C10aliphatic wherein up to two methylene units of the C1-C10aliphatic are optionally replaced with —C(O)—, NH, or N(C1-C6aliphatic);
• L2 is optionally substituted with 1-3 halo;
• L3 is C1-C12aliphatic wherein up to three methylene units of the C1-C12aliphatic are optionally replaced with —C(O)—, NH, or N(C1-C6aliphatic);
• L3 is optionally substituted with 1-3 halo;
• each JH is independently halogen, —CN, —NO2, XJ, QJ, or XJ-QJ;
• or two JH groups bound to the same carbon atom, together with the carbon atom to which they are bound, optionally form —C═N—OH, —C(O)—, or Ring HH;
• Ring HH is a 3-8 membered saturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur;
• optionally substituted with 1-4 occurrences of JHH;
• JHH is halo, CN, oxo, XJ, QJ, or XJ-QJ;
• XJ is a C1-C10 aliphatic, wherein up to 4 methylene units of the C1-C10 aliphatic are optionally replaced with —O—, —NH, N(C1C6aliphatic), —S—, —C(O)—, —C(═NOH)—, —S(O)—, —S(O)2—, P, or P(O);
• XJ is optionally substituted with 0-6 occurrences of halo, OH, or C1-4alkyl;
• or optionally substituted with 0-1 occurrences of CN;
• QJ is a 3-7 membered monocyclic saturated, fully unsaturated, partially unsaturated, or aromatic ring optionally having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur;
• or an 8-12 membered saturated, fully unsaturated, partially unsaturated, or aromatic ring optionally having 1-6 heteroatoms selected from oxygen, nitrogen, or sulfur;
• wherein each QJ is optionally substituted with 1-6 occurrences of halo, oxo, CN, or C1-6alkyl, wherein up to 2 methylene units of said C1-6alkyl are optionally replaced with —O—, —NH, N(C1-C6aliphatic), —S—, —C(O)—, —S(O)—, or —S(O)2—.